Malaria drug resistance confirmed in ethiopia: study raises alarm
NCT ID NCT07527182
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether the malaria parasite in Ethiopia is becoming resistant to artemisinin, the main drug used to treat it. Researchers tested 277 patients across five sites, checking if parasites were still in the blood three days after treatment and looking for a specific genetic marker. The goal was to confirm if drug resistance is present, which could affect how malaria is treated in the region.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTEMISININ-RESISTANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bako Health Center
Bako, Ethiopia
-
Mehoni Health Center
Mersa, Tigray, Ethiopia
-
Metahara Health Center
Metehara, Ethiopia
-
Rama Health Center
Rama, Ethiopia
-
Workamba Health Center
Kechemo, Ethiopia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can smarter antibiotic use curb Drug-Resistant infections?
- Can a single shot of a genetically weakened malaria parasite train the body to fight off the real thing?
- Could a Liver-Stage malaria vaccine shield mothers and babies?
- Cancer drug could supercharge malaria treatment and beat resistance
- Smart wristbands may spot malaria before symptoms strike
- One shot to stop malaria? new injection tested in rwanda